GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (FRA:ER4) » Definitions » Policy Acquisition Expense

Emergent BioSolutions (FRA:ER4) Policy Acquisition Expense


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Emergent BioSolutions Business Description

Traded in Other Exchanges
Address
300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.